Cagrilintide

Cagrilintide is a long-acting analog of amylin, a hormone released from the pancreas alongside insulin after meals. Natural amylin helps signal fullness, but its effects are short-lived. Cagrilintide is engineered for a longer duration of action, providing sustained satiety support across a whole week on a single injection. The mechanism is distinct from GLP-1 agonists: it slows gastric emptying and increases satiety signals through the amylin pathway rather than the GLP-1 pathway. This is why it is most commonly used as a complement to a GLP-1 or GLP-1/GIP agonist rather than on its own. The combination of semaglutide plus cagrilintide - sometimes referred to as CagriSema - has been studied in trials and shows additive effects on weight loss. Cagrilintide is indicated primarily for fat loss support and is a good fit for people who are already on a GLP-1 agonist and want to augment fullness signaling through a second, complementary pathway. It is given as a once-weekly subcutaneous injection on the same day each week. Dose range is 0.3 to 2.4 mg, titrated upward based on response. Like the GLP-1 agents it is often paired with, slow titration is used to manage GI tolerance. Cagrilintide is investigational - it has not received FDA approval as a standalone agent. It is not appropriate during pregnancy. The data base is emerging: human trial data exists but long-term approval is pending. Exact dosing, titration, and whether it fits your specific protocol are decisions made with a licensed provider in the PepDepo network at your consult.